Lowering Cost and Increasing Access to Drugs Without Jeopardizing Innovation

JAMA - Journal of the American Medical Association

Volumn 321, Issue 16, 2019, Pages 1571-1573

  Califf, Robert M ^a,b   Slavitt, Andrew ^c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VERILY LIFE SCIENCES   (United States)

^c United States of Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BIOSIMILAR AGENT; PRESCRIPTION DRUG;

AWARENESS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG MARKETING; EDITORIAL; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL STATUS; FUNDING; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEPATITIS C; HIGH INCOME COUNTRY; LIFE EXPECTANCY; MEDICARE; PRIORITY JOURNAL; QUALITY OF LIFE; REIMBURSEMENT;

COST CONTROL; DRUG COSTS; PRESCRIPTION DRUGS;

EID: 85065115333     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2019.3846     Document Type: Editorial

References (17)

1. Zafar SY, Abernethy AP. Financial toxicity, I: a new name for a growing problem. Oncology (Williston Park). 2013; 27 (2): 80-81, 149. 23530397
2. Zheng Z, Han X, Guy GP Jr, Do cancer survivors change their prescription drug use for financial reasons? findings from a nationally representative sample in the United States. Cancer. 2017; 123 (8): 1453-1463. doi: 10.1002/cncr.30560 28218801
3. Woolf SH, Aron L. Failing health of the United States. BMJ. 2018; 360: k496. doi: 10.1136/bmj.k496 29437654
4. Horvath JC, Anderson GF. The states as important laboratories for federal prescription drug cost-containment efforts [published online April 23, 2019]. JAMA. doi: 10.1001/jama.2019.2189
5. Dusetzina SB, Bach PB. Prescription drugs-list price, net price, and the rebate caught in the middle [published online March 6, 2019]. JAMA. doi: 10.1001/jama.2019.2445 30840047
6. Humphries B, Xie F. Canada's amendment to patented drug price regulation: a prescription for global drug cost control? [published online March 29, 2019]. JAMA. 2019. doi: 10.1001/jama.2019.2280 30924840
7. Gurwitz JH, Pearson SD. Novel therapies for an aging population: grappling with price, value, and affordability [published online April 23, 2019]. JAMA. doi: 10.1001/jama.2019.2633
8. Vogler S, Haasis M, Dedet G, Lam J, Pedersen BK; World Health Organization. Medicines reimbursement policies in Europe. 2018. http://www.euro.who.int/--data/assets/pdf-file/0011/376625/pharmaceutical-reimbursement-eng.pdf?ua=1. Accessed March 26, 2019.
9. Drug Price Competition and Patent Term Restoration Act. Pub L No. 98-417, 98 Stat 1585. https://www.congress.gov/bill/98th-congress/senate-bill/01538. Accessed April 2, 2019.
10. Generic drugs. US Food and Drug Administration website. https://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/GenericDrugs/default.htm. Accessed March 26. 2019.
11. Blackstone EA, Fuhr JP Jr, Pociask S. The health and economic effects of counterfeit drugs. Am Health Drug Benefits. 2014; 7 (4): 216-224. 25126373
12. Personal importation. US Food and Drug Administration website. https://www.fda.gov/forindustry/importprogram/importbasics/ucm432661.htm. Accessed March 26, 2019.
13. Schulman KA, Dabora M. The relationship between pharmacy benefit managers (PBMs) and the cost of therapies in the US pharmaceutical market: a policy primer for clinicians. Am Heart J. 2018; 206: 113-122. doi: 10.1016/j.ahj.2018.08.006 30447542
14. Zupello S. The latest Instagram influencer frontier? medical promotions. Vox. February 15, 2019. https://www.vox.com/the-goods/2019/2/15/18211007/medical-sponcon-instagram-influencer-pharmaceutical. Accessed March 26, 2019.
15. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019; 20 (2): 273-286. doi: 10.1093/biostatistics/kxx069 29394327
16. Califf RM, Robb MA, Bindman AB, Transforming evidence generation to support health and health care decisions. N Engl J Med. 2016; 375 (24): 2395-2400. doi: 10.1056/NEJMsb1610128 27974039
17. National Academies of Sciences, Engineering, and Medicine. Potential strategies for a way forward. In: Real-World Evidence Generation and Evaluation of Therapeutics-Workshop: Proceedings of a Workshop. Washington, DC: National Academies Press; February 15, 2017: 39-50.